New drug combo shows promise for rare uterine cancer in early trial
NCT ID NCT05870761
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial is testing whether combining niraparib (a PARP inhibitor) and dostarlimab (an immunotherapy) can shrink or control recurrent or persistent uterine serous carcinoma. The study enrolled 8 women whose cancer had returned after standard chemotherapy. Researchers are measuring how many patients respond and how long the benefit lasts.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- niraparib and dostarlimab
- What this could lead to
- If this combination works, it could offer a new treatment option for women with recurrent uterine serous carcinoma that has not responded to standard chemotherapy.
- What could go wrong
- This is a very small phase II trial with only 8 participants, so results may not apply to a larger population. The combination may not shrink tumors or improve survival, and side effects from PARP and PD-1 inhibitors can be serious.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT ENDOMETRIAL SEROUS ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.